Dr. Aplan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Rockville Pike
# 8901
Bethesda, MD 20889Phone+1 301-435-5005Fax+1 301-496-0047
Education & Training
National Capital ConsortiumFellowship, Pediatric Hematology/Oncology, 1987 - 1992
University at BuffaloResidency, Pediatrics, 1983 - 1987
Pennsylvania State University College of MedicineClass of 1983
Certifications & Licensure
MD State Medical License 1987 - 2026- American Board of Pediatrics Pediatrics
Publications & Presentations
PubMed
- 84 citationsThe high-mobility group A1a/signal transducer and activator of transcription-3 axis: An achilles heel for hematopoietic malignancies?Joelle Hillion, Surajit Dhara, Takita Felder Sumter, Mita Mukherjee, Francescopaolo Di Cello
Cancer Research. 2008-12-15 - 1 citationsThe evolution of preclinical models for myelodysplastic neoplasms.Alain Mina, Steven Pavletic, Peter D Aplan
Leukemia. 2024-04-01 - 24 citationsMouse models of myelodysplastic syndromes.Sarah H. Beachy, Peter D. Aplan
Hematology/oncology Clinics of North America. 2010-04-01
Abstracts/Posters
- Idh2R140Q Cooperates with NHD13 to Induce Immature T Cell Leukemia By Targeting Early T Cell Progenitors or DN2 ThymocytesPeter D. Aplan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Disruption of the Normal Hematopoietic Hierarchy Leading to Stem Cell Exhaustion in an Animal Model of Myelodysplastic SyndromePeter D. Aplan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- A Novel DNA Methyltransferase Inhibitor Is Effective in an In Vivo Model of Myelodysplastic Syndrome2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Mice with a Unique Mutator Phenotype Allow Detection of Lymphoid Leukemia Tumor Suppressor Genes2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Engineered Bcor Mutations Lead to Acute Lymphoblastic Leukemia of Progenitor B-1 Lymphocyte Origin in a Sensitized Background2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Grant Support
- Pre-Clinical Studies Of Therapy For Myelodysplastic SyndromeNational Cancer Institute2010–2011
- Mechanisms Of Chromosomal TranslocationNational Cancer Institute2010–2011
- Collaborative Pathways That LEAD To LeukemiaNational Cancer Institute2010–2011
- Activation Of Proto-Oncogenes By Chromosomal TranslocationNational Cancer Institute2010–2011
- Mechanisms Of Chromosomal TranslocationDivision Of Clinical Sciences - Nci2009
- Activation Of Proto-Oncogenes By Chromosomal TranslocationDivision Of Clinical Sciences - Nci2009
- Pre-Clinical Studies Of Therapy For Myelodysplastic SyndromeDivision Of Basic Sciences - Nci2009
- Collaborative Pathways That LEAD To LeukemiaDivision Of Basic Sciences - Nci2009
- Pre-Clinical Studies Of Therapy For Myelodysplastic SyndromeNational Cancer Institute2008
- Mechanisms Of Chromosomal TranslocationNational Cancer Institute2007–2008
- Activation Of Proto-Oncogenes By Chromosomal TranslocationNational Cancer Institute2007–2008
- Activation Of Proto-Oncogenes By Chromosomal TranslocatiDivision Of Clinical Sciences - Nci2002–2006
- Mechanisms Of Chromosomal TranslocationDivision Of Clinical Sciences - Nci2001–2006
- Activation Of Proto-Oncogenes--Chromosomal TranslocationDivision Of Clinical Sciences - Nci2001
- SCL Gene Dysregulation And T Cell LeukemiaNational Cancer Institute1996–1999
- Chromosomal Translocations Caused By TOPO II InhibitorsNational Cancer Institute1997–1998
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
